Dr. Yun began her career at Hanmi Pharmaceuticals, took the major role in managing all activities associated with the clinical development programs for key assets including long-acting insulin, GLP-1 agonist and GLP-1/GCG dual agonist. She engaged in full courses of drug development, ranging from CDP/TPP development, clinical strategy formulation and operations, licensing out and co-development with partners. She also served as a strategic consultant in IQVIA, worked on consulting projects for key business decisions, including business planning and strategy formulation, asset valuation and pricing & reimbursement strategy for various drugs etc.
In September 2019, Dr. Yun joined to GI Innovation and has led clinical collaboration agreement of company’s immunooncology asset with global pharmaceutical companies, including MSD and AstraZeneca. She is now serving as a head of clinical development.
Dr. Yun is a registered pharmacist in Korea and was educated at School of Pharmacy, Sunkyunkwan University, where she received her PhD in pharmacology in 2012.